Syndax Pharmaceuticals Inc — Director's Dealing 2021

Dec 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Syndax Pharmaceuticals Inc (SNDX)
CIK: 0001395937
Period of Report: 2021-12-20

Reporting Person: Legault Pierre (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-20	Common Stock	M	20000.00	$7.08	Acquired	36000.00	Direct
2021-12-20	Common Stock	S	20000.00	$21.0125	Disposed	16000.00	Direct
2021-12-22	Common Stock	M	24000.00	$7.88	Acquired	40000.00	Direct
2021-12-22	Common Stock	S	24000.00	$22.0086	Disposed	16000.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-20	Stock Options (Right to buy)	$7.08	M	20000.00	Disposed	2027-01-04	Common Stock (20000.00)	Direct
2021-12-22	Stock Options (Right to buy)	$7.88	M	24000.00	Disposed	2029-06-10	Common Stock (24000.00)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 63,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested.

F2: The sale prices ranged from $21.00 to $21.0238.

F3: The sale prices ranged from $22.00 to $22.02.

F4: This option is fully vested.